
Zantac Heartburn Medication
In October 2019, a class-action lawsuit was filed against Sanofi-Aventis U.S., Sanofi US Services, Chattem, Inc., and Boehringer Ingelheim Pharmaceuticals for allegedly failing to disclose that the over-the-counter heartburn medication Zantac exposes users to unsafe levels of the carcinogen N-Nitrosodimethylamine (NDMA). (Dimesky et al v. Sanofi-Aventis U.S., LLC, Sanofi US Services Inc., Chattem, Inc., and Boehringer Ingelheim Pharmaceuticals, Inc., Case No. 19-cv-1517, D. CT.)
Class-Action Tracker

The Latest

Ribena – There’s No Taste Like Home
This soft drink reminds consumers of the good old days.

US Cellular: ‘Four Free Phones and Four Lines for $90’
What you need to know about this offer.

Monetizing Minors: Aneliese German (aka Lisi Shops)
What’s this kidfluencer doing promoting a “youth cream”?

This Secretive Company Built An Empire By Hawking Bad Financial And Health Advice On Facebook
Emily Baker-White, Forbes

Instaflex Advanced
Can this joint supplement back up its stiff promises?